PIPELINE RESEARCH AND DEVELOPMENT PRECLINICAL CLINICAL

Vanarix is currently working on several projects in the pipeline.

In 2022, a First-In-Man study using Autologous Cartibeads™ (produced from the patient’s own cells) started and has successfully completed recruitment. Preliminary data from this study suggest initial safety and efficacy of Autologous Cartibeads™ for treating knee cartilage lesions.

At present, a First-In-Man study is underway to treat knee cartilage lesions using Allogeneic Cartibeads™ (derived from donor cells). Recruitment is expected to be completed in 2024, with results available in 2025.

Vanarix is also conducting a pre-clinical study using Allogeneic Cartibeads™ to treat osteochondral lesions. Results are expected for 2025.

Equine Allogeneic Cartibeads™ were developed to treat osteonchondritis dissecans in horses. In 2024, several horses have already received this treatment. Preliminary data show promising cartilage regeneration.

Finally, Cartibeads™ could be used as a disease model, for instance, to screen and develop disease-modifying osteoarthritis drugs (DMOAD).